As I write this, both the US and the world are seeing an upsurge in COVID-19. There has been a 46% spike in hospitalized patients, and in the past seven days more than a half-million more Americans have contracted the coronavirus. According to the Johns Hopkins dashboard that tracks COVID-19 cases all over the world, […]
Articles
This will surely not be the last time Doc Gumshoe turns his attention to the pandemic that is now imposing misery on many parts of the world. I need to acknowledge that when what was then generally called the Wuhan virus first came to my attention, I expressed the view that, despite the dire […]
We’re used to seeing biotech stocks surge because of the results of a clinical trial… but it’s quite crazy to see the whole market pinning its hopes on a clinical trial. Gilead’s (GILD) Remdisivir had some weak results leak last week and that helped inspire the market selloff (“Oh no, we won’t get a drug […]
We’re now a month past the “bottom” that the market hit on March 23 in the heat of the panic, and although the world is thinking about opening up now and throwing ever more “rescue” money from helicopters, we’re still not all that close to predicting when “back to normal” might hit… and just now […]
It’s hard to stay away from the coronavirus pandemic, even though Doc Gumshoe basically has no information that’s any different from what’s flooding into your inboxes or TV screens or, for those of us who are still members of the ancient fellowship of newspaper readers, the pages of our daily newspapers. But a few […]
I’ve gotten a few questions about the latest Technology Profits Confidential (currently $79/yr) tease from Ray Blanco, so although it’s a few weeks old now, and started circulating right in the heat of the first coronavirus downturn in mid-March, I thought I’d take a look today. It is still a current ad, I got it […]
Ian Wyatt has been out over the past couple weeks with some “webinars” in which he talks up the coronavirus outbreak (for an hour!) and then ends his show with a tease about several “special reports” on the stocks he thinks will make you a lot of money as we fight COVID-19… and, of course, […]
Don’t look to Doc Gumshoe to keep you up to the minute on the spread of the Wuhan coronavirus. The figures I’m quoting below are as of mid-day today, February 18th. These will have changed by the time you see this piece, and they may be unreliable in the first place. But, […]
Please indulge Doc Gumshoe while he presents his musings on what’s going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as which ones are getting the short straw. My impressions and conclusions are in some cases only loosely based on […]
This particular bit of news leaves your friend Doc Gumshoe shaking his head in puzzlement. To wit, in the US it is expected that there will be a substantial shortage of physicians in the upcoming years. The American Association of Medical Colleges predicts that this shortage may reach about 122,000 physicians by the year […]
Chances are not many of us observed New Year’s Eve with celebratory toasts to the glorious year gone by. Rather, we bid goodbye to 2018 and hoped 2019 would be a better year – for ourselves, our near and dear, our country, and our planet. However, as I wade through the volumes of healthcare-related stuff […]
For those of us who live in this part of the country and spend any time messing around outdoors in the grass and weeds, this is the time to be careful about Lyme disease. I had a bout of Lyme 16 years ago, and it descended on me when we were on vacation, driving through […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
Remember Ernie Tremblay’s pitch about a “tiny South Texas lab” that was about to cure every disease using its revolutionary CD19 Cancer Vaccine technology, and ignite a bidding war following its fantastical release of exciting information on June 23? Well, it’s back. Not the stock, that’s still languishing around where it was before Tremblay got […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his old articles and his most recent comments on his Stock Gumshoe page.] “Keep it quiet. (Go slow.) […]
[Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and recent comments here.] The State of Things is a classy 1982 Wim Wenders film in which a film […]
The folks at Money Map/Money Morning have really taken the “most aggressive advertisers” mantle from the other Agora affiliates of late — we can pretty much count on a new promotional campaign from this publisher becoming the “most asked about” pitch by our readers almost instantly, whether it’s Michael Robinson or Keith Fitz-Gerald or Dr. […]
Newsletter copywriters are no different from other marketers: they will do whatever it takes to get attention by playing off of something or someone that has celebrity or notoriety. In the past that’s meant implying that some big celebrity investor has a connection to a “secret” stock or technique, or that someone high up in […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, writes for us a couple times a month on medicine and health issues. He is not a physician, but explains the science and the data well, and helps provide some background understanding and perspective that often benefits both investors and folks who are attentive […]
[ed note: Michael Jorrin, who I dubbed “Doc Gumshoe,” is a longtime medical writer (not a doctor) who shares his thoughts with Gumshoe readers a couple times a month. He usually does not specifically cover investment ideas, and his words and opinions are his own — his past columns can be found here] Lots of […]
Everybody’s got to deviate from the norm. —Rush John Galsworthy wrote that the beginning and endings of human undertakings are untidy. It was never more so than in the early days of HCV, a mere 20 years ago, when a plague first called “non-A non-B hepatitis” began vexing people, progressively scarring their livers and behaving […]
[Ed. Note: Dr. KSS is an MD and PhD who writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see his past articles and recent comments here.] You’re probably getting it right by now—writing “2016” and not “2015.” […]
This pitch is not all that tough to decipher for those who are seasoned biotech investors, but it’s generating a lot of questions for us today so I thought we’d get a quick answer out for you — it’s certainly a stock that gets plenty of attention, so you won’t need much of a head […]
Golly, most people who might subscribe to investment newsletters are baby boomers. And most of that generation is just a few years past their midlife crisis… so you can be pretty sure that a “silent epidemic” will get them to read your ad, yes? Apparently so, if the questions rolling in to Gumshoe HQ over […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. His bio, past articles, and most recent comments can be seen here. Enjoy!] OUT of the night that covers me, Black as the Pit from pole to pole, I thank […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He choses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Enjoy!] In his smoky baritone, singer Stuart Staples of British midlands musical act Tindersticks is bemoaning how he suspects the woman he […]
[Ed Note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he sometimes mentions a couple publicly traded companies). His words and opinions are his own. […]
“I firmly believe that if the whole materia medica could be sunk to the bottom of the sea, it would be all the better for mankind and all the worse for the fishes.” — Oliver Wendell Holmes, M. D., Professor of Medicine , Harvard “With all his conscience and one eye askew, So false he […]
The Zed Files[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Enjoy!] It could be the premise of a tawdry unrated movie that teenage boys sneak glimpses of on Netflix when they’re home alone. […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] His tidily rhyming names perhaps destined him for fame. While Jack Kerouac’s work and popularity were before my time, his cultural and literary restlessness assure him […]
[ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]
[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars! You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. His previous columns can be found here. Enjoy!] Every New Year, a friend and I flew to Boston. She’d gone to medical school […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own, and he has agreed to our trading restrictions.] Want to see something really cool? A hot video clip from a steamy biotech thriller? Watch this. Better yet, when you pull up the video viewing frame, […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. His topics, words and opinions are his own. Enjoy!] It’s the second reel of conspiracy film Shooter, and Mark Wahlberg, whom government schemers are trying to frame for assassination, has just been shot twice. In the back of a stolen FBI car, […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Here we are, solidly in the postmodern 21st century, “so late in the goddam day,” as one of novelist Martin Amis’s characters says, and what […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]
What’s the commonest reason for admission to hospital of people 65 and over? Mull that question, as it provides context. Think of people you know. At least one probably has this condition. It’s not diabetes. It’s not heart attacks. And it is not infectious. But it kills and lots of people have it. Part II […]
[Ed. Note: Here is the latest contribution from Dr. KSS, who writes for the Irregulars about medicine and biomedical stocks. As always, he has agreed to our trading restrictions and his words and thoughts are his own.] The Belle of the Everglades How To Profit From The Cure First of Two Parts Of the many […]
[Ed. Note: Here is our second installment from Dr. KSS, formerly known as “karmaswimswami” in Gumshoe discussion threads. Dr. KSS has agreed to our trading and disclosure restrictions, and he’s not offering you personal investment or medical advice. As with all of our columnists, we don’t assign topics or opinions and do just a bit of light […]
[ed note: We feature the musings of our favorite health and medicine writer, Michael Jorrin, a couple times a month, and we’ve taken the liberty of calling him “Doc Gumshoe” (he’s not a doctor). You’ll find no stock picks in his pieces, but hopefully will get plenty of insight into the medical matters he explains […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
And judging from the 6x normal volume today I'd say RVLGF is his pick. I got an email from him yesterday saying he had ...
This one's looking a little more positive for Frank now that earnings provided some optimism (a "miss" but some positive...
Interestingly (I'm a CRA subscriber), now that C has hit $50, despite reaching his stop loss, Curzio has announced he's ...
Frank does talk about stop losses and I get the impression he typically uses them in his newsletters, though I don't kno...
Agree on MLP, covered that one here: https://www.stockgumshoe.com/reviews/curzio-venture-opportunities/whats-curzios-nes...
Don't get caught by this "Crypto Intelligence" fraud by Frank Curzio. There was a big multi-months promotion by Frank Cu...
Frank Curzio is a snake oil salesman that really needs to look into the mirror and realize he is doing way more harm the...
Performance of Curzio's stock picks has been poor to date, hopefully, that will change with time. As mentioned below, th...
Selling is hard, especially when you have to admit that you were wrong in an idea you were really sure about. I haven...
Does anybody have any idea which biotech-stock (DNA sequencing) this can be that's being promoted by Frank Curzio? Th...
I don't really care that not all the factors are in place, and this is also the reason why the price has been priced ver...
FYI, it's getting hard to find a mining newsletter publisher that's NOT excited about Northern Dynasty these days -- Sta...
Yes, I could also sell a small position in not too distant future, since my position is starting to be too big since I g...
Lithium X is a regular and favorite paid pump of CEO.ca. Stay away. Having Katusa involved just makes it worse. Kat...
Hendrixnuzzles, in an interview with Frank Curzio yesterday, Marin noted there were three ways right now to participate ...
I commented on Northern Dynasty (NAK) some time back (and was also trying to figure out Mr Katusa's new gold pick, but I...
I am too very cautious at the moment, but have around 15% of my portfolio in silver/gold-mining stocks. Just bought NAK...
Frank Curzio just did a great interview of Mr. Katusa and UEC. I give Katusa kudos for his passion and commitment to the...
I just listened to the Brad Hopman video where he introduced Frank Curzio as just joining their group of Adventure Capi...
Frank Curzio has teased that one a few times as well for his Phase 1 newsletter at Stansberry....
Frank Curzio recommended LPI in Oct 2012 @ 19.96. Currently a hold with a "buy up to" price of $22.50...
Travis Frank Curzio is at it again. The Marijuana story no one is telling Comment ? Pat...
I'm sure many of you got this email, but for those that didn't, Frank Curzio has written an article saying that a "great...
I just sat through listening to Frank Curzio tell me about 43 small stocks that could earn up to 30% dividend, and he wo...
In mid-May 2013 Frank Curzio specifically mentioned this company in another newsletter (probably one of the free ones fr...
The email I saw on this today (Frank Curzio Phase 1 Investor) talked about a small North American driller who somehow go...
Actually, the pitchman is Frank Curzio, but what is the stock?...
The Next Great Royalty Business By Frank Curzio, editor, Small Stock Specialist He is talking about Altius Minerals...
I actually have talked to Frank Curzio, exchanged e-mails, and offered a stock pick to him a several years ago. At th...
Frank Curzio recommended the stock last week, which coincided with the price spike...
Thanks Travis for all the good work you do. I am new to all this speculative investing on Jr miners but this latest teas...
TRAVIS You are the man!!! I just got done reading the tease by Frank Curzio and have been a long time holder of Royal G...
Travis, Any information on Frank Curzio new hot stock that's 100% American made "Eagle Diesel" which is dubbed as the ...
Gold Standard Ventures has sure been a nice one this year! That was a Frank Curzio recco for his Phase 1, and it so hap...
I heard Frank Curzio talking about trans ocean (RIG). he said they were getting over $600,000 per day drilling. I wonder...
looks like Stansberry is pushing this one again. got a newsletter today promising The "gold sands" discovery of a lif...
What Gold Sands is Frank Curzio teasing? Apparently the gold is under 1500 meters of water and 5000 miles from New Yor...
It depends what kind of investor you are and what you are looking for. Don't expect any of these guys to bet 1000% If...
GMXR (GMX resources) is a play on the Williston Basin. It recently fell from about $5 to about $1.70 per share, despite...
Once again, good job Travis. I love reading Frank Curzio (I subscribe to his Penny Stock Specialist Newsletter), but I&...
Does anyone know what Frank Curzio is touting for his Phase 1 newsletter as the "New Royal Gold"? ...
Dr. Eifrig's colleague, Frank Curzio, has a brand new teaser for Phase 1 called the "Next Royal Gold." I...
it is on Stanberry's Phase 1 Investor by an analyst named Frank Curzio who has an excelllent track record ...
Is there a way to find out if Groote Resources has paid Frank Curzio or Stanberry Associates to promote this stock? ...
Frank Curzio hyped Triquint Semiconductor (TQNT), didn't he? I bought at $6.60 per share, held on for about 6 mont...
Penny Stock Specialist Frank Curzio does a good job of finding low priced stocks with good prospects. I have had mixe...
You were right on your pick of IO which looks like a real winner, especially now that oil prices are rising because of t...
MPET was discussed by Frank Curzio in the S&A "Off the Record" back in Nov 2009 issue. Sandstorm is not n...
Don't have much track record yet with Frank Curzio, but he appears to be a careful analyst, sincere and dedicated and wi...
Isn't Frank Curzio the guy who was in a stock-picking contest a few years back on CNBC with a monkey?.... and lost!...